Effects and mechanisms of betulinic acid on improving EGFR TKI‐resistance of lung cancer cells
- 23 August 2018
- journal article
- research article
- Published by Wiley in Environmental Toxicology
- Vol. 33 (11) , 1153-1159
Abstract
Epidermal growth factor receptor (EGFR) mutations have been identified in approximately 55% of lung cancer patients in Taiwan. Gefitinib (Iressa) and Erlotinib (Tarceva) are the first‐generation targeting drugs to patients with EGFR gene mutants a work by inhibiting tyrosine kinase activity. However, resistance in EGFR‐mutated patients to first‐generation tyrosine kinase inhibitor (TKI) therapy after 8‐11 months of treatment has occurred. Betulinic acid (BetA) is a pentacyclic triterpenoid natural product derived from widespread plants. BetA has been reported to have a cytotoxic effect in several cancers. The purpose of this study is to investigate the effects and mechanisms of BetA on dampening EGFR TKI‐resistance of lung cancer cells. Our study has demonstrated by MTT assay that combining BetA and an EGFR TKI increased the cytotoxicity against EGFR TKI‐resistance lung cancer cells. Based on flow cytometry, combination treatments of BetA with an EGFR TKI enhanced Sub‐G1 accumulation, induced apoptosis and induced mitochondrial membrane potential loss. Using western blotting, BetA and EGFR TKI combined treatments inhibited cell cycle related protein and triggered apoptosis‐ and autophagy‐ related protein expression. Taken together, our data suggests that a target therapy combining BetA with an EGFR TKI improves drug efficacy in EGFR TKI‐resistant lung cancer cells.Keywords
This publication has 26 references indexed in Scilit:
- Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overviewJournal of Translational Medicine, 2011
- Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factorsBMC Cancer, 2011
- Betulinic acid inhibits endotoxin‐stimulated phosphorylation cascade and pro‐inflammatory prostaglandin E2 production in human peripheral blood mononuclear cellsBritish Journal of Pharmacology, 2010
- The continuing search for antitumor agents from higher plantsPhytochemistry Letters, 2010
- Key regions of VDAC1 functioning in apoptosis induction and regulation by hexokinaseBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Betulinic Acid for Cancer Treatment and PreventionInternational Journal of Molecular Sciences, 2008
- Hexokinase II Detachment from Mitochondria Triggers Apoptosis through the Permeability Transition Pore Independent of Voltage-Dependent Anion ChannelsPLOS ONE, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007